Base de dados : MEDLINE
Pesquisa : D12.776.124.486.485.114.224.060.782 [Categoria DeCS]
Referências encontradas : 1052 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 106 ir para página                         

  1 / 1052 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28449657
[Au] Autor:Adachi JD; Bone HG; Daizadeh NS; Dakin P; Papapoulos S; Hadji P; Recknor C; Bolognese MA; Wang A; Lin CJF; Wagman RB; Ferrari S
[Ad] Endereço:McMaster University, 501-25 Charlton Ave E., Hamilton, ON, L8N 1Y2, Canada. jd.adachi@sympatico.ca.
[Ti] Título:Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
[So] Source:BMC Musculoskelet Disord;18(1):174, 2017 04 27.
[Is] ISSN:1471-2474
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study. METHODS: To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not. We subsequently employed a Kaplan-Meier multiple imputation (KMMI) approach to consider subjects who discontinued as if they remained enrolled with a 0%, 20%, 50%, and 100% increase in fracture risk compared with participants remaining on study. RESULTS: Extension enrollees were generally similar to nonparticipants in median age (71.9 and 73.1 years, respectively), mean total hip bone mineral density T-score (-1.9 and -2.0, respectively), and probability of fracture risk by Fracture Risk Assessment Tool (FRAX ) at FREEDOM baseline (16.9% and 17.7% for major osteoporotic fracture and 6.7% and 7.4% for hip fracture, respectively). When we assumed a doubled fracture risk (100% increase) after discontinuation in KMMI analyses, nonvertebral fracture rate estimates were only marginally higher than the observed rates for both the crossover group (10.32% vs 9.16%, respectively) and the long-term group (7.63% vs 6.63%, respectively). CONCLUSION: The observation of continued denosumab efficacy over 8 years of treatment was robust and does not seem to be explained by depletion of susceptible subjects. TRIAL REGISTRATION: ClincalTrials.gov registration number NCT00523341 ; registered August 30, 2007.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/uso terapêutico
Denosumab/uso terapêutico
Fraturas do Quadril/tratamento farmacológico
Fraturas por Osteoporose/tratamento farmacológico
Pacientes Desistentes do Tratamento
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Feminino
Fraturas do Quadril/diagnóstico por imagem
Fraturas do Quadril/epidemiologia
Seres Humanos
Masculino
Meia-Idade
Fraturas por Osteoporose/diagnóstico por imagem
Fraturas por Osteoporose/epidemiologia
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12891-017-1520-6


  2 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370211
[Au] Autor:Hayes AR; Brungs D; Pavlakis N
[Ad] Endereço:Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
[Ti] Título:Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
[So] Source:PLoS One;13(1):e0191455, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related events associated with bone metastases. However, it is uncertain whether they play a disease-modifying role earlier in the course of the disease. METHODS: Medline, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews and ASCO conference proceedings were searched for randomized controlled trials that compared osteoclast inhibitors with placebo and/or standard of care (SOC) in patients with high-risk, non-metastatic prostate cancer. The primary outcome measure was incidence of new bone metastases; secondary outcomes included overall survival (OS), prostate cancer specific survival, mortality unrelated to prostate cancer, toxicity and health related quality of life outcomes. Results are presented as relative risk (RR) with 95% confidence intervals (CI). RESULTS: Six randomized controlled trials (5947 participants) were included, five evaluating bisphosphonates and one denosumab. Overall, there was no difference in incidence of bone metastases between participants treated with osteoclast inhibitors versus placebo/SOC (RR 1.09, 95%CI 0.84-1.41, p = 0.51) however significant heterogeneity was observed between studies. The denosumab trial was the largest and only positive trial amongst the included studies (RR 0.83, 95%CI 0.73-0.95, p = 0.007). No significant difference was observed in OS (RR 0.99 95% CI 0.89-1.10, p = 0.84) nor prostate cancer specific survival (RR 1.12 95%CI 0.93-1.36, p = 0.24). Most studies reported increased rates of osteonecrosis of the jaw (5% or less) and hypocalcemia (2% or less) with osteoclast inhibitors. CONCLUSIONS: While there is limited evidence that bisphosphonates alter the natural history of high-risk, non-metastatic prostate cancer, denosumab delays onset of bone metastases in this patient population. Neither class of osteoclast inhibitor demonstrated an impact on survival outcomes. Future trials with better defined patient selection and a robust definition for high risk disease is critical.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/uso terapêutico
Neoplasias Ósseas/prevenção & controle
Neoplasias Ósseas/secundário
Osteoclastos/efeitos dos fármacos
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Denosumab/uso terapêutico
Difosfonatos/uso terapêutico
Seres Humanos
Masculino
Osteoclastos/patologia
Avaliação de Resultados (Cuidados de Saúde)
Neoplasias da Próstata/patologia
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191455


  3 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339529
[Au] Autor:Adler RA
[Ad] Endereço:Endocrinology and Metabolism SectionMcGuire Veterans Affairs Medical Center, Division of Endocrinology,Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA Robert.adler@va.gov.
[Ti] Título:MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
[So] Source:Eur J Endocrinol;178(3):R81-R87, 2018 Mar.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Modern osteoporosis treatment began in the mid-1990s with the approval of amino-bisphosphonates, anti-resorptive agents that have been shown to decrease osteoporotic fracture risk by about half. In 2005, the first cases of atypical femoral fractures (AFF), occurring in the shaft of the femur, were reported. Since then, more cases have been found, leading to great concern among patients and a dramatic decrease in bisphosphonate prescribing. The pathogenesis and incidence of AFF are reviewed herein. Management and an approach to prevention or early detection of AFF are also provided. Denosumab, a more recently approved anti-resorptive medication has also been associated with AFF. Long-term management of osteoporosis and prevention of fracture are challenging in light of this serious but uncommon side effect, yet with an aging population osteoporotic fracture is destined to increase in frequency.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/efeitos adversos
Fraturas do Fêmur/induzido quimicamente
Osteoporose/tratamento farmacológico
Fraturas por Osteoporose/prevenção & controle
[Mh] Termos MeSH secundário: Conservadores da Densidade Óssea/uso terapêutico
Denosumab/efeitos adversos
Denosumab/uso terapêutico
Difosfonatos/efeitos adversos
Difosfonatos/uso terapêutico
Seres Humanos
Medição de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-1002


  4 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252655
[Au] Autor:Park A; Cipriano CA; Hill K; Kyriakos M; McDonald DJ
[Ad] Endereço:Departments of Orthopaedic Surgery (A.P., C.A.C., and D.J.M.) and Pathology (K.H. and M.K.), Washington University School of Medicine, St. Louis, Missouri.
[Ti] Título:Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
[So] Source:JBJS Case Connect;6(3):e78, 2016 Jul-Sep.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: Giant cell tumor (GCT) of bone was first described almost 200 years ago, but the optimal treatment continues to evolve. We present a patient with a pelvic GCT who was treated with embolization, 20 months of denosumab therapy, and resection. Histologically, the tumor consisted of degenerated GCT, bone, and fibrous tissue. After 7 months, the patient was found to have osteosarcoma at the site of the initial lesion as well as pulmonary metastases. CONCLUSION: The apparent malignant transformation of a GCT of bone treated initially with denosumab indicates that close follow-up is warranted.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/efeitos adversos
Neoplasias Ósseas/patologia
Denosumab/efeitos adversos
Tumor de Células Gigantes do Osso/patologia
Segunda Neoplasia Primária/patologia
Osteossarcoma/patologia
Ossos Pélvicos/patologia
[Mh] Termos MeSH secundário: Adulto
Neoplasias Ósseas/diagnóstico por imagem
Neoplasias Ósseas/tratamento farmacológico
Neoplasias Ósseas/cirurgia
Transformação Celular Neoplásica
Evolução Fatal
Feminino
Tumor de Células Gigantes do Osso/diagnóstico por imagem
Tumor de Células Gigantes do Osso/tratamento farmacológico
Tumor de Células Gigantes do Osso/cirurgia
Seres Humanos
Segunda Neoplasia Primária/etiologia
Osteossarcoma/etiologia
Ossos Pélvicos/diagnóstico por imagem
Ossos Pélvicos/efeitos dos fármacos
Ossos Pélvicos/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00024


  5 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252651
[Au] Autor:Zhang Y; Ilaslan H; Krishnaney AA; Bauer TW
[Ad] Endereço:Department of Pathology, Robert J. Tomsich Pathology & Laboratory Medicine Institute (Y.Z. and T.W.B.), Department of Diagnostic Radiology (H.I.), Department of Neurosurgery and Center for Spine Health (A.A.K. and T.W.B.), and Department of Orthopaedic Surgery (T.W.B.), Cleveland Clinic, Clevela
[Ti] Título:Morphological Transformation of Giant-Cell Tumor of Bone After Treatment with Denosumab: A Case Report.
[So] Source:JBJS Case Connect;6(3):e74, 2016 Jul-Sep.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: Denosumab, an inhibitor of RANKL (receptor activator of nuclear factor κ-B ligand), was recently introduced for the treatment of giant-cell tumor of bone (GCTB). We describe the clinical, radiographic, and histological features of a GCTB of the spine in a 24-year-old woman that progressed after neoadjuvant treatment with denosumab. Disappearance of the multinuclear osteoclastic giant cells was accompanied by newly formed woven bone, which was deposited in interconnected strands with a prominent fibrovascular stroma that was histologically and radiographically similar to that of an osteoblastoma. CONCLUSION: Pathologists, radiologists, and surgeons should be aware of this post-treatment transformation to avoid misdiagnosis.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/uso terapêutico
Denosumab/uso terapêutico
Tumor de Células Gigantes do Osso/patologia
Neoplasias da Coluna Vertebral/patologia
Vértebras Torácicas/patologia
[Mh] Termos MeSH secundário: Conservadores da Densidade Óssea/farmacologia
Denosumab/farmacologia
Feminino
Tumor de Células Gigantes do Osso/diagnóstico por imagem
Tumor de Células Gigantes do Osso/tratamento farmacológico
Tumor de Células Gigantes do Osso/cirurgia
Seres Humanos
Laminectomia
Neoplasias da Coluna Vertebral/diagnóstico por imagem
Neoplasias da Coluna Vertebral/tratamento farmacológico
Neoplasias da Coluna Vertebral/cirurgia
Vértebras Torácicas/diagnóstico por imagem
Vértebras Torácicas/efeitos dos fármacos
Vértebras Torácicas/cirurgia
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00015


  6 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28816971
[Au] Autor:Ji T; Yang Y; Wang Y; Sun K; Guo W
[Ad] Endereço:aMusculoskeletal Tumor Center bDepartment of Pathology, People's Hospital, Peking University, Beijing, China.
[Ti] Título:Combining of serial embolization and denosumab for large sacropelvic giant cell tumor: Case report of 3 cases.
[So] Source:Medicine (Baltimore);96(33):e7799, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Both serial arterial embolization (SAE) and denosumab have been proved to be effective in treatment for giant cell tumor (GCT). There is potential synergic effect of combining two methods. The purpose of current study is to justify a new treatment strategy of combination of SAE and denosumab as neoadjuvant or stand-alone treatment for large sacropelvic giant cell tumor. PATIENT CONCERNS: Pelvic and sacral GCTs tend to be very large size and vascular. The concerns of surgical treatment were invasiveness of extensive surgery, intraoperative hemorrhage, nerve function jeopardized and local recurrence. However, SAE alone may not be adequate for complete removal of the tumor. DIAGNOSES: All the three cases were proved to be GCT by core-needle biopsy. Post-treatment pathological change was confirmed by further biopsy. INTERVENTIONS: The patient in Case 1 diagnosed of large recurrent sacral GCT received 6 times of endovascular embolizations with 2-month interval and started on denosumab simultaneously after first session of embolization. The second case was a 22-year-old female presented with a massive iliosacral tumor. SAE was performed for 3 sessions and the denosumab was started simultaneously. The patients was on treatment for half year. Both patients experienced a dramatic decrease in symptoms and concomitant improvement in function after the first embolization and weekly injection of denosumab. Tumor removal was performed on patient in case 2. The last case was a pelvic GCT and the patient received SAE and denosumab for half year. The tumor was then removed with purpose of complete cure. OUTCOMES: The first patient was still on denosumab with stable tumor. The other two patients were both free of recurrence after surgical removal of the tumors. No denosumab was used postoperatively. LESSONS: We reported the first three cases treated by combination of SAE and denosumab in the literature and aim to raise an alternative method for large GCT at challenging anatomical locations, for which surgery would carry significant risk. SAE and denosumab can synergically promote sclerosis and result in significant decrease in pain. It is reasonable to consider using SAE combined with denosumab neoadjuvantly to reduce the extensiveness and morbidity of surgery, however further investigation is warranted.
[Mh] Termos MeSH primário: Neoplasias Ósseas/terapia
Denosumab/uso terapêutico
Embolização Terapêutica/métodos
Tumores de Células Gigantes/terapia
[Mh] Termos MeSH secundário: Adulto
Neoplasias Ósseas/tratamento farmacológico
Terapia Combinada
Feminino
Tumores de Células Gigantes/tratamento farmacológico
Seres Humanos
Masculino
Meia-Idade
Pelve
Sacro
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007799


  7 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28785760
[Au] Autor:Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
[Ad] Endereço:From University of Toronto, University Health Network, Odette Cancer Centre, and Princess Margaret Hospital, Toronto; McMaster University and Juravinski Cancer Centre, Hamilton; University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa; and Western University and London Health Sciences Cent
[Ti] Título:Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
[So] Source:Ann Intern Med;167(5):341-350, 2017 Sep 05.
[Is] ISSN:1539-3704
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Bone health is a significant concern in men with prostate cancer. Purpose: To evaluate the effectiveness of drug, supplement, and lifestyle interventions aimed at preventing fracture, improving bone mineral density (BMD), or preventing or delaying osteoporosis in men with nonmetastatic prostate cancer. Data Sources: Ovid MEDLINE (1946 to 19 January 2017), EMBASE (1980 to 18 January 2017), and the Cochrane Database of Systematic Reviews (19 January 2017). Study Selection: Randomized trials and systematic reviews of trials that were published in English; involved men with nonmetastatic prostate cancer; and compared bone-targeted therapies with placebo, usual care, or other active treatments. Data Extraction: Two reviewers independently extracted study characteristics and assessed study risk of bias for each outcome. Data Synthesis: Two systematic reviews and 28 reports of 27 trials met inclusion criteria. All trials focused on men with nonmetastatic prostate cancer who were initiating or continuing androgen deprivation therapy (ADT). Bisphosphonates were effective in increasing BMD, but no trial was sufficiently powered to detect reduction in fractures. Denosumab improved BMD and reduced the incidence of new radiographic vertebral fractures in 1 high-quality trial. No trials compared calcium or vitamin D versus placebo. Three lifestyle intervention trials did not show a statistically significant difference in change in BMD between exercise and usual care. Limitations: Most trials were of moderate quality. Only 2 randomized controlled trials were designed to examine fracture outcomes. Potential harms of treatments were not evaluated. Conclusion: Both bisphosphonates and denosumab improve BMD in men with nonmetastatic prostate cancer who are receiving ADT. Denosumab also reduces risk for radiographic vertebral fractures, based on 1 trial. More trials studying fracture outcomes are needed in this population. Primary Funding Source: Program in Evidence-Based Care.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/efeitos adversos
Antineoplásicos Hormonais/efeitos adversos
Conservadores da Densidade Óssea/uso terapêutico
Osteoporose/prevenção & controle
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas de Androgênios/uso terapêutico
Antineoplásicos Hormonais/uso terapêutico
Densidade Óssea/efeitos dos fármacos
Denosumab/uso terapêutico
Seres Humanos
Masculino
Osteoporose/induzido quimicamente
Fraturas por Osteoporose/prevenção & controle
Toremifeno/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Antineoplastic Agents, Hormonal); 0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab); 7NFE54O27T (Toremifene)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.7326/M16-2577


  8 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28760341
[Au] Autor:Okamatsu N; Sakai N; Karakawa A; Kouyama N; Sato Y; Inagaki K; Kiuchi Y; Oguchi K; Negishi-Koga T; Takami M
[Ad] Endereço:Department of Orthopaedic Surgery, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; Department of Pharmacology, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; Department of Pharmacology, School of Dentistry, Show
[Ti] Título:Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns.
[So] Source:Biochem Biophys Res Commun;491(3):614-621, 2017 Sep 23.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Denosumab, a fully human monoclonal antibody that neutralizes receptor activator of nuclear factor-κB ligand (RANKL) and blocks osteoclast differentiation, has received approval in Japan for use as an anti-resorptive drug for osteoporosis and skeletal-related events (SREs) in patients with solid cancer. Denosumab is contraindicated during pregnancy, though the effects of blocking RANKL activity on pregnant mothers and their newborns are unclear. We used mice to investigate the effects of an anti-RANKL antibody on maternal and newborn health. Mothers injected with the anti-RANKL antibody had increased bone mass as compared with the controls, while osteoclast number and the level of tartrate-resistant acid phosphatase (TRAP) in serum were increased at the end of pregnancy. Newborn mice exposed to the antibody in utero were normally born, but showed increased bone mass and died within 48 h after birth. None of the newborns were found to have milk in their stomachs, suggesting that they died due to a maternal defect in lactation. Consistent with this, anti-RANKL antibody-injected mothers displayed impaired mammary gland development. However, fostering by healthy surrogate mothers rescued only 33% of the antibody-exposed newborns, suggesting that neonatal mortality was due, at least in part, to an intrinsic defect in the newborns. Our findings show that anti-RANKL antibody administration during pregnancy results in not only an undesirable increase in bone mass, but also has harmful effects on newborn survival.
[Mh] Termos MeSH primário: Denosumab/efeitos adversos
Transtornos da Nutrição do Lactente/induzido quimicamente
Transtornos da Nutrição do Lactente/imunologia
Transtornos da Lactação/induzido quimicamente
Transtornos da Lactação/imunologia
Morte Perinatal/etiologia
Ligante RANK/imunologia
[Mh] Termos MeSH secundário: Animais
Animais Recém-Nascidos
Conservadores da Densidade Óssea/administração & dosagem
Conservadores da Densidade Óssea/efeitos adversos
Denosumab/administração & dosagem
Denosumab/imunologia
Feminino
Seres Humanos
Recém-Nascido
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Gravidez
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (RANK Ligand); 0 (Tnfsf11 protein, mouse); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE


  9 / 1052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28668858
[Au] Autor:Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
[Ad] Endereço:Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan miya.yoshi@hotmail.co.jp.
[Ti] Título:Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
[So] Source:Anticancer Res;37(7):3667-3671, 2017 07.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Androgen deprivation therapy (ADT) is a mainstay therapy for prostate cancer (PCa). ADT induces bone loss and increases the risk of osteoporosis and fractures. Recently, loss of bone quality has received attention as a factor that causes loss of bone strength independent of bone mineral density (BMD). Pentosidine has been identified as a surrogate marker of bone quality. Therefore, bone quality markers were evaluated retrospectively in PCa patients receiving ADT with or without denosumab. PATIENTS AND METHODS: This study included 46 PCa patients. Twenty patients received denosumab. We measured pentosidine as bone quality marker and TRACP-5b as bone turnover marker. Pre- and 12-month BMD was measured in the lumbar spine and femoral neck. RESULTS: In the denosumab group (D+), BMD at the lumbar spine was increased by 6.7% compared with the group that did not receive denosumab (D-) at 12 months (p=0.0015). BMD at the femoral neck was increased by 3.1% at 12 months (p=0.0076). The mean value of TRAP-5b was lower in the D+ group than the D- group at 12 months (p<0.001). The mean serum levels of pentosidine in the D+ group were decreased by -39.6% compared with the D- group at 12 months (p=0.0036). CONCLUSION: Denosumab increased BMD during ADT for PCa and inhibited the increasing levels of serum pentosidine in PCa patients undergoing ADT.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/efeitos adversos
Biomarcadores/metabolismo
Densidade Óssea/efeitos dos fármacos
Remodelação Óssea/efeitos dos fármacos
Denosumab/administração & dosagem
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/administração & dosagem
Arginina/análogos & derivados
Arginina/metabolismo
Conservadores da Densidade Óssea/administração & dosagem
Colo do Fêmur/efeitos dos fármacos
Colo do Fêmur/metabolismo
Fraturas Ósseas/induzido quimicamente
Fraturas Ósseas/metabolismo
Seres Humanos
Vértebras Lombares/efeitos dos fármacos
Vértebras Lombares/metabolismo
Lisina/análogos & derivados
Lisina/metabolismo
Masculino
Meia-Idade
Osteoporose/induzido quimicamente
Osteoporose/metabolismo
Neoplasias da Próstata/metabolismo
Estudos Retrospectivos
Fosfatase Ácida Resistente a Tartarato/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Biomarkers); 0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab); 94ZLA3W45F (Arginine); BJ4I2X2CQJ (pentosidine); EC 3.1.3.2 (ACP5 protein, human); EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase); K3Z4F929H6 (Lysine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170703
[St] Status:MEDLINE


  10 / 1052 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28585373
[Au] Autor:Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Robinson AB; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
[Ad] Endereço:Yale University, New Haven, Connecticut.
[Ti] Título:2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
[So] Source:Arthritis Rheumatol;69(8):1521-1537, 2017 Aug.
[Is] ISSN:2326-5205
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength. The guideline addresses initial assessment and reassessment in patients beginning or continuing long-term (≥3 months) glucocorticoid (GC) treatment, as well as the relative benefits and harms of lifestyle modification and of calcium, vitamin D, bisphosphonate, raloxifene, teriparatide, and denosumab treatment in the general adult population receiving long-term GC treatment, as well as in special populations of long-term GC users. RESULTS: Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned oral bisphosphonate regimen but continue to receive GC treatment. Recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high-dose GC treatment, are also made. CONCLUSION: This guideline provides direction for clinicians and patients making treatment decisions. Clinicians and patients should use a shared decision-making process that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/uso terapêutico
Glucocorticoides/efeitos adversos
Osteoporose/prevenção & controle
Fraturas por Osteoporose/prevenção & controle
Doenças Reumáticas/tratamento farmacológico
[Mh] Termos MeSH secundário: Cálcio na Dieta/uso terapêutico
Consenso
Denosumab/uso terapêutico
Difosfonatos/uso terapêutico
Seres Humanos
Osteoporose/induzido quimicamente
Osteoporose/tratamento farmacológico
Fraturas por Osteoporose/induzido quimicamente
Fraturas por Osteoporose/tratamento farmacológico
Cloridrato de Raloxifeno/uso terapêutico
Reumatologia
Sociedades Médicas
Teriparatida/uso terapêutico
Estados Unidos
Vitamina D/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Calcium, Dietary); 0 (Diphosphonates); 0 (Glucocorticoids); 10T9CSU89I (Teriparatide); 1406-16-2 (Vitamin D); 4EQZ6YO2HI (Denosumab); 4F86W47BR6 (Raloxifene Hydrochloride)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE
[do] DOI:10.1002/art.40137



página 1 de 106 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde